Actual Medicinal Product (AMP) Mirabegron 50mg modified-release tablets (Astellas Pharma Ltd)

Stability Information

(Some stability information inherited from generic)

Stability
compatible logo Suitable for use in MCAs, although use is likely to be off-label. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the products mirabegron 50mg modified-release tablets (Astellas Pharma Ltd).

Generic
Mirabegron
Formulation
Mirabegron 50mg modified-release tablets
  • Mirabegron
    • Mirabegron 50mg modified-release tablets

      • Mirabegron 50mg modified-release tablets (Astellas Pharma Ltd)